DK1381590T3 - 3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander - Google Patents

3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander

Info

Publication number: DK1381590T3
Authority: DK; Denmark
Prior art keywords: dione; chemokine receptor; receptor ligands; cxc chemokine; cyclobutene
Prior art date: 2001-04-16

Application number

DK02739172T

Other languages

Danish (da)

English (en)

Inventor

Arthur G Taveras

Cynthia J Aki

Richard W Bond

Jianping Chao

Michael Dwyer

Johan A Ferreira

Jianhua Chao

Younong Yu

John J Baldwin

Bernd Kaiser

Ge Li

J Robert Merritt

Kingsley H Nelson

Laura L Rokosz

Original Assignee

Schering Corp

Pharmacopeia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-16

Filing date

2002-04-15

Publication date

2007-10-22

2002-04-15 Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp

2007-10-22 Application granted granted Critical

2007-10-22 Publication of DK1381590T3 publication Critical patent/DK1381590T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)

DK02739172T 2001-04-16 2002-04-15 3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander DK1381590T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28402601P	2001-04-16	2001-04-16
PCT/US2002/012681 WO2002083624A1 (en)	2001-04-16	2002-04-15	3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Publications (1)

Publication Number	Publication Date
DK1381590T3 true DK1381590T3 (da)	2007-10-22

Family

ID=23088576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK07010711.5T DK1818325T3 (da)	2001-04-16	2002-04-15	3,4-di-substituerede cyklobuten-1,2-dioner som CXC-chemokin receptorligander
DK02739172T DK1381590T3 (da)	2001-04-16	2002-04-15	3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK07010711.5T DK1818325T3 (da)	2001-04-16	2002-04-15	3,4-di-substituerede cyklobuten-1,2-dioner som CXC-chemokin receptorligander

Country Status (31)

Country	Link
EP (2)	EP1381590B1 (es)
JP (3)	JP4499993B2 (es)
KR (2)	KR100952531B1 (es)
CN (2)	CN1289471C (es)
AR (1)	AR035825A1 (es)
AT (2)	ATE458715T1 (es)
AU (3)	AU2002311841B2 (es)
BR (1)	BRPI0208957B8 (es)
CA (1)	CA2444031C (es)
CY (2)	CY1109908T1 (es)
CZ (1)	CZ20032831A3 (es)
DE (2)	DE60220778T2 (es)
DK (2)	DK1818325T3 (es)
EC (1)	ECSP034809A (es)
ES (2)	ES2287284T3 (es)
HK (2)	HK1057538A1 (es)
HU (1)	HUP0401783A3 (es)
IL (3)	IL158262A0 (es)
MX (1)	MXPA03009441A (es)
MY (2)	MY149050A (es)
NO (2)	NO330790B1 (es)
NZ (3)	NZ560453A (es)
PE (1)	PE20021084A1 (es)
PL (2)	PL207255B1 (es)
PT (2)	PT1818325E (es)
RU (1)	RU2344123C9 (es)
SI (2)	SI1818325T1 (es)
SK (1)	SK287598B6 (es)
TW (2)	TWI316930B (es)
WO (1)	WO2002083624A1 (es)
ZA (1)	ZA200307905B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7132445B2 (en)	2001-04-16	2006-11-07	Schering Corporation	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) *	2001-04-16	2004-06-03	Schering Corporation	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1434775A1 (en)	2001-10-12	2004-07-07	Schering Corporation	3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
US8246969B2 (en)	2001-11-16	2012-08-21	Skinmedica, Inc.	Compositions containing aromatic aldehydes and their use in treatments
US6878709B2 (en)	2002-01-04	2005-04-12	Schering Corporation	3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
WO2003080053A1 (en)	2002-03-18	2003-10-02	Schering Corporation	Combination treatments for chemokine-mediated diseases
GB0218326D0 (en) *	2002-08-07	2002-09-11	Glaxo Group Ltd	Compounds
PE20040570A1 (es)	2002-10-09	2004-08-30	Pharmacopeia Drug Discovery	Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
US7893096B2 (en)	2003-03-28	2011-02-22	Novartis Vaccines And Diagnostics, Inc.	Use of small molecule compounds for immunopotentiation
EP1720844B1 (de)	2003-04-03	2009-04-29	MERCK PATENT GmbH	Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
EP2168956B8 (en)	2003-04-18	2013-05-01	Merck Sharp & Dohme Corp.	Synthesis of 2-Hydroxy-N,N-Dimethyl-3-[[2-[1(r) - (5-Methyl-2-Furanyl) Propyl] -3, 4-Dioxo-1-Cyclobuten-1-Yl]amino] Benzamide
KR101204247B1 (ko)	2003-07-22	2012-11-22	아스텍스 테라퓨틱스 리미티드	3,4-이치환된 1ｈ-피라졸 화합물 및 그의 시클린 의존성키나제 (ｃｄｋ) 및 글리코겐 합성효소 키나제-3(ｇｓｋ-3) 조정제로서 용도
GB0320983D0 (en) *	2003-09-08	2003-10-08	Biofocus Plc	Compound libraries
CA2538745A1 (en)	2003-09-23	2005-03-31	Fermion Oy	Preparation of quetiapine
GB0324269D0 (en)	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
ATE406356T1 (de)	2003-12-19	2008-09-15	Schering Corp	Thiadiazole als cxc- und cc- chemokinrezeptorliganden
WO2005068460A1 (en)	2003-12-22	2005-07-28	Schering Corporation	Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
DE602005022986D1 (de) *	2004-01-30	2010-09-30	Schering Corp	Kristalline polymorphe eines cxc-chemokinrezeptorliganden
JP2007525521A (ja) *	2004-02-27	2007-09-06	シェーリング　コーポレイション	Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物
EP1634573A1 (en) *	2004-08-16	2006-03-15	The Procter and Gamble Company	2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
BRPI0514379A (pt)	2004-08-16	2008-06-10	Procter & Gamble	compostos de 2-(amino ou amino substituìdo) fenol-5, 6-substituìdo, composições para tingimento contendo os mesmos, e uso das mesmas
AU2005286731A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
CA2580844A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
BRPI0515505A (pt)	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
BRPI0515488A (pt)	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados de heterocìclicos e seu uso como agentes terapêuticos
TW200626139A (en)	2004-09-20	2006-08-01	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
BRPI0515483A (pt)	2004-09-20	2008-07-22	Xenon Pharmaceuticals Inc	derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
BRPI0515489A (pt)	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
DE602004021404D1 (de)	2004-12-23	2009-07-16	Gpc Biotech Ag	Quadratsäurederivate mit antiproliferativer Wirkung
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
WO2007130075A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
MX2008000366A (es)	2005-06-29	2008-03-07	Schering Corp	Oxadiazoles di-sustituidos como ligandos del receptor cxc-quimiocina.
ES2353401T3 (es)	2005-06-29	2011-03-01	Schering Corporation	Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos del receptor de cxc-quimiocina.
DE102005035742A1 (de) *	2005-07-29	2007-02-01	Merck Patent Gmbh	Quadratsäurederivate II
AU2006316452B2 (en) *	2005-11-24	2013-01-10	Dompe' Farmaceutici S.P.A.	(R)-arylalkylamino derivatives and pharmaceutical compositions containing them
CA2647592C (en) *	2006-05-26	2014-01-28	Abbott Laboratories	Inhibitors of polo-like kinases
CN101500544B (zh)	2006-06-12	2012-08-08	先灵公司	Cxcr2或cxcr1与cxcr2两者的选择性拮抗剂的药物制剂和组合物及其用于治疗炎性疾病的使用方法
CN101511809A (zh) *	2006-07-07	2009-08-19	先灵公司	作为cxc-趋化因子受体配体的3,4-二取代的环丁烯-1,2-二酮
US8450348B2 (en)	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
CN101772485A (zh) *	2007-06-06	2010-07-07	诺瓦提斯公司	抗炎的被取代的环丁烯二酮化合物
CN101932553A (zh) *	2007-07-03	2010-12-29	先灵公司	合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体
JP5816082B2 (ja) *	2008-06-24	2015-11-17	トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔＡ／Ｓ	ニコチンアミドの阻害剤としてのスクアリン酸誘導体
UA103198C2 (en)	2008-08-04	2013-09-25	Новартис Аг	Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) *	2008-12-05	2010-06-10	Novartis Ag	3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
MX2012013197A (es)	2010-05-12	2013-04-03	Abbvie Inc	Inhibidores de indazol de cinasa.
FR2961695B1 (fr) *	2010-06-29	2012-07-06	Galderma Res & Dev	Utilisation de composes dans le traitement ou la prevention de troubles cutanes
SG191879A1 (en)	2011-01-07	2013-08-30	Allergan Inc	Melanin modification compositions and methods of use
KR102024955B1 (ko)	2011-09-02	2019-09-24	노파르티스 아게	치환된 시클로부텐디온 항염 화합물의 콜린 염
FR2981934B1 (fr) *	2011-10-28	2013-12-20	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr)	2011-10-28	2013-12-20	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr)	2011-10-28	2015-08-07	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103242210B (zh) *	2012-02-09	2014-09-24	北京艾百诺科技有限公司	含有取代方酸的乙酸妙林酯及其应用
AR092809A1 (es)	2012-03-16	2015-05-06	Axikin Pharmaceuticals Inc	3,5-diaminopirazol como inhibidor de quinasa
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
CN103382192A (zh) *	2012-05-04	2013-11-06	同创医药(苏州)有限公司	N-单取代哌嗪衍生物的制备
CA2905242C (en)	2013-03-15	2016-11-29	Pfizer Inc.	Indole compounds that activate ampk
CN103214327A (zh) *	2013-03-22	2013-07-24	郑州泰基鸿诺药物科技有限公司	一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
US10046002B2 (en)	2013-08-02	2018-08-14	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
US10561676B2 (en) *	2013-08-02	2020-02-18	Syntrix Biosystems Inc.	Method for treating cancer using dual antagonists of CXCR1 and CXCR2
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
FR3030515B1 (fr) *	2014-12-23	2017-01-20	Galderma Res & Dev	Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
WO2016106309A1 (en)	2014-12-23	2016-06-30	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
TWI734715B (zh) *	2015-11-19	2021-08-01	美商卡默森屈有限公司	趨化因子受體調節劑
TWI724056B (zh)	2015-11-19	2021-04-11	美商卡默森屈有限公司	Ｃｘｃｒ２抑制劑
WO2018073248A1 (en)	2016-10-17	2018-04-26	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Prognosis of demyelinating diseases patients and treatment thereof
AU2018318075B2 (en) *	2017-08-14	2023-04-13	Allergan, Inc.	3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
WO2019067332A1 (en)	2017-09-27	2019-04-04	Merck Sharp & Dohme Corp.	COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
EP3737366A4 (en)	2018-01-08	2022-07-27	ChemoCentryx, Inc.	METHOD OF TREATMENT OF GENERALIZED PUSTULOUS PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2
MX2021003318A (es)	2018-09-21	2021-05-14	Pfizer	Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6.
CN110041309B (zh) *	2019-04-04	2022-01-28	广东工业大学	一种2-羧基哌嗪连接的他克林-8-氨基(羟基)喹啉衍生物及制备与应用
BR112022006226A2 (pt) *	2019-10-07	2022-06-28	De Shaw Res Llc	Compostos heterocíclicos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
KR20220162364A (ko) *	2021-06-01	2022-12-08	부산대학교 산학협력단	신규 스퀘어아마이드 유도체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0692915A (ja) *	1992-07-28	1994-04-05	Sumitomo Metal Ind Ltd	１，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
GB9312210D0 (en) *	1993-06-14	1993-07-28	Smithkline Beecham Plc	Chemical compounds
GB9316111D0 (en) *	1993-08-04	1993-09-22	Pfizer Ltd	Benzopyrans
US5354763A (en) *	1993-11-17	1994-10-11	American Home Products Corporation	Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) *	1994-11-04	1995-11-14	American Home Products Corporation	Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
ATE176223T1 (de) *	1994-11-16	1999-02-15	American Home Prod	Diaminocyclobuten-3,4-dione
TR199802695T2 (xx) *	1996-06-27	1999-04-21	Smithkline Beecham Corporation	IL-8 Resept�r kar��tlar�
US5840764A (en) *	1997-01-30	1998-11-24	American Home Products Corporation	Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
WO1998033763A1 (en) *	1997-01-30	1998-08-06	American Home Products Corporation	Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6211220B1 (en) *	1998-11-23	2001-04-03	Cell Pathways, Inc.	Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
AU2357600A (en) *	1998-12-14	2000-07-03	American Home Products Corporation	3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesionmediated by vla-4
WO2000035864A1 (en) *	1998-12-16	2000-06-22	Bayer Aktiengesellschaft	New biphenyl and biphenyl-analogous compounds as integrin antagonists
US6518283B1 (en) *	1999-05-28	2003-02-11	Celltech R&D Limited	Squaric acid derivatives
AR033803A1 (es) *	2000-03-01	2004-01-07	Smithkline Beecham Corp	Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
EP1284956A4 (en) *	2000-05-30	2005-08-24	Smithkline Beecham Corp	ANTAGONISTS OF THE IL-8 RECEPTOR
EP1351933B1 (en) *	2001-01-16	2006-11-22	SmithKline Beecham Corporation	Il-8 receptor antagonists
US20040110954A1 (en) *	2001-03-30	2004-06-10	Palovich Michael R.	Methods of synthesizing phenol-contining compounds
WO2003080053A1 (en) *	2002-03-18	2003-10-02	Schering Corporation	Combination treatments for chemokine-mediated diseases

2002
- 2002-04-15 MY MYPI20070922A patent/MY149050A/en unknown
- 2002-04-15 PT PT07010711T patent/PT1818325E/pt unknown
- 2002-04-15 RU RU2003133448/04A patent/RU2344123C9/ru not_active IP Right Cessation
- 2002-04-15 WO PCT/US2002/012681 patent/WO2002083624A1/en active Application Filing
- 2002-04-15 DE DE60220778T patent/DE60220778T2/de not_active Expired - Lifetime
- 2002-04-15 SK SK1288-2003A patent/SK287598B6/sk not_active IP Right Cessation
- 2002-04-15 PT PT02739172T patent/PT1381590E/pt unknown
- 2002-04-15 DE DE60235507T patent/DE60235507D1/de not_active Expired - Lifetime
- 2002-04-15 JP JP2002581381A patent/JP4499993B2/ja not_active Expired - Lifetime
- 2002-04-15 NZ NZ560453A patent/NZ560453A/en unknown
- 2002-04-15 IL IL15826202A patent/IL158262A0/xx unknown
- 2002-04-15 DK DK07010711.5T patent/DK1818325T3/da active
- 2002-04-15 PL PL367129A patent/PL207255B1/pl unknown
- 2002-04-15 NZ NZ529551A patent/NZ529551A/en not_active IP Right Cessation
- 2002-04-15 NZ NZ543869A patent/NZ543869A/en not_active IP Right Cessation
- 2002-04-15 KR KR1020037013527A patent/KR100952531B1/ko not_active IP Right Cessation
- 2002-04-15 CN CNB028119797A patent/CN1289471C/zh not_active Expired - Fee Related
- 2002-04-15 CN CNA2006101374093A patent/CN1990457A/zh active Pending
- 2002-04-15 MY MYPI20021372A patent/MY138202A/en unknown
- 2002-04-15 AT AT07010711T patent/ATE458715T1/de active
- 2002-04-15 SI SI200230898T patent/SI1818325T1/sl unknown
- 2002-04-15 CA CA2444031A patent/CA2444031C/en not_active Expired - Lifetime
- 2002-04-15 ES ES02739172T patent/ES2287284T3/es not_active Expired - Lifetime
- 2002-04-15 SI SI200230572T patent/SI1381590T1/sl unknown
- 2002-04-15 HU HU0401783A patent/HUP0401783A3/hu unknown
- 2002-04-15 DK DK02739172T patent/DK1381590T3/da active
- 2002-04-15 AU AU2002311841A patent/AU2002311841B2/en not_active Expired
- 2002-04-15 AT AT02739172T patent/ATE365154T1/de active
- 2002-04-15 EP EP02739172A patent/EP1381590B1/en not_active Expired - Lifetime
- 2002-04-15 CZ CZ20032831A patent/CZ20032831A3/cs unknown
- 2002-04-15 ES ES07010711T patent/ES2340207T3/es not_active Expired - Lifetime
- 2002-04-15 BR BR0208957-2 patent/BRPI0208957B8/pt not_active IP Right Cessation
- 2002-04-15 EP EP07010711A patent/EP1818325B1/en not_active Expired - Lifetime
- 2002-04-15 KR KR1020097026265A patent/KR20100008794A/ko not_active Application Discontinuation
- 2002-04-15 MX MXPA03009441A patent/MXPA03009441A/es active IP Right Grant
- 2002-04-15 AR ARP020101371A patent/AR035825A1/es not_active Application Discontinuation
- 2002-04-15 PL PL390082A patent/PL208928B1/pl unknown
- 2002-04-16 TW TW091107670A patent/TWI316930B/zh active
- 2002-04-16 TW TW096102669A patent/TW200736196A/zh unknown
- 2002-04-16 PE PE2002000318A patent/PE20021084A1/es not_active Application Discontinuation
2003
- 2003-10-02 IL IL158262A patent/IL158262A/en not_active IP Right Cessation
- 2003-10-09 ZA ZA2003/07905A patent/ZA200307905B/en unknown
- 2003-10-15 NO NO20034612A patent/NO330790B1/no not_active IP Right Cessation
- 2003-10-16 EC EC2003004809A patent/ECSP034809A/es unknown
2004
- 2004-01-21 HK HK04100477A patent/HK1057538A1/xx not_active IP Right Cessation
2006
- 2006-08-24 AU AU2006203679A patent/AU2006203679A1/en not_active Abandoned
2007
- 2007-08-07 CY CY20071101059T patent/CY1109908T1/el unknown
2008
- 2008-02-13 HK HK08101594.0A patent/HK1107818A1/xx not_active IP Right Cessation
2009
- 2009-05-20 JP JP2009122594A patent/JP2009179641A/ja active Pending
- 2009-10-25 IL IL201754A patent/IL201754A0/en unknown
- 2009-12-08 JP JP2009278869A patent/JP5294418B2/ja not_active Expired - Lifetime
2010
- 2010-04-29 CY CY20101100380T patent/CY1109989T1/el unknown
- 2010-08-20 AU AU2010212484A patent/AU2010212484B2/en not_active Expired
2011
- 2011-01-12 NO NO20110050A patent/NO20110050L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2444031A1 (en)	2002-10-24
NZ529551A (en)	2006-02-24
RU2003133448A (ru)	2005-06-10
ES2340207T3 (es)	2010-05-31
DE60220778T2 (de)	2008-03-06
SK12882003A3 (sk)	2004-06-08
HUP0401783A3 (en)	2005-06-28
HK1107818A1 (en)	2008-04-18
JP4499993B2 (ja)	2010-07-14
ECSP034809A (es)	2004-02-26
KR20100008794A (ko)	2010-01-26
EP1818325B1 (en)	2010-02-24
MY138202A (en)	2009-05-29
AU2006203679A1 (en)	2006-09-14
CN1289471C (zh)	2006-12-13
PT1381590E (pt)	2007-08-06
BRPI0208957B1 (pt)	2018-10-09
RU2344123C9 (ru)	2009-05-20
JP2010053151A (ja)	2010-03-11
BRPI0208957B8 (pt)	2021-05-25
NO20034612L (no)	2003-12-08
MY149050A (en)	2013-07-15
CY1109989T1 (el)	2014-09-10
NO20034612D0 (no)	2003-10-15
IL158262A0 (en)	2004-05-12
DE60220778D1 (en)	2007-08-02
AU2002311841B2 (en)	2006-09-14
AR035825A1 (es)	2004-07-14
AU2010212484A1 (en)	2010-09-09
BR0208957A (pt)	2004-06-22
EP1818325A3 (en)	2008-02-13
IL201754A0 (en)	2010-06-16
PL207255B1 (pl)	2010-11-30
CN1516687A (zh)	2004-07-28
JP2004532846A (ja)	2004-10-28
CY1109908T1 (el)	2014-09-10
PE20021084A1 (es)	2002-12-20
IL158262A (en)	2012-05-31
MXPA03009441A (es)	2004-02-12
TWI316930B (en)	2009-11-11
NO20110050L (no)	2003-12-08
EP1381590B1 (en)	2007-06-20
SK287598B6 (sk)	2011-03-04
RU2344123C2 (ru)	2009-01-20
AU2010212484B2 (en)	2012-04-12
ZA200307905B (en)	2005-03-30
TW200736196A (en)	2007-10-01
HK1057538A1 (en)	2004-04-08
EP1818325A2 (en)	2007-08-15
KR100952531B1 (ko)	2010-04-12
JP5294418B2 (ja)	2013-09-18
PL208928B1 (pl)	2011-06-30
NZ560453A (en)	2009-03-31
PL367129A1 (en)	2005-02-21
CA2444031C (en)	2012-02-21
NZ543869A (en)	2007-09-28
ATE365154T1 (de)	2007-07-15
DE60235507D1 (de)	2010-04-08
PT1818325E (pt)	2010-05-12
SI1818325T1 (sl)	2010-06-30
CN1990457A (zh)	2007-07-04
DK1818325T3 (da)	2010-05-31
HUP0401783A2 (hu)	2005-01-28
KR20030092074A (ko)	2003-12-03
EP1381590A1 (en)	2004-01-21
NO330790B1 (no)	2011-07-18
ES2287284T3 (es)	2007-12-16
SI1381590T1 (sl)	2007-10-31
JP2009179641A (ja)	2009-08-13
ATE458715T1 (de)	2010-03-15
CZ20032831A3 (cs)	2004-03-17
WO2002083624A1 (en)	2002-10-24

Publication	Publication Date	Title
NO20110050L (no)	2003-12-08	3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander
NO20033424D0 (no)	2003-07-31	3,4-disubstituerte syklobuten-1,2-dioner som CXC- kemokinreseptorantagonister
NO20043022L (no)	2004-07-15	5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
ITTO20010940A0 (it)	2001-10-04	,,sedia,,
NO20042373L (no)	2004-06-07	Nye 1,2,4-tiadiazoliumderivater som melanokortinreseptormodulatorer
DE60216115D1 (de)	2006-12-28	BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
NO20041560L (no)	2004-05-11	1,6-nafthyridinderivater som antidiabetiske midler
NL1021752A1 (nl)	2003-04-28	Katalysators.
DK1414440T3 (da)	2007-05-21	N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
NO20041075L (no)	2004-03-15	Ny 1, 2, 4-triazolforbindelse
AU2003207460A1 (en)	2003-07-24	3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
DE60210598D1 (de)	2006-05-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
DE60129750D1 (de)	2007-09-13	Antiblend-, antibeschlagselement
ITMI20022423A1 (it)	2003-05-28	Prolungamento di ugello.
AR028248A1 (es)	2003-04-30	Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
DK1381596T3 (da)	2007-02-05	Thiazolylsubstituerede carbocykliske 1,3-dioner som pesticider
BR0204153B1 (pt)	2010-10-19	transmissão.
NO20044413L (no)	2004-10-18	1,2-Dihydropyrazol-3-oner som cytokinmediatorer
ATE332902T1 (de)	2006-08-15	3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika
ITTO20020745A1 (it)	2003-02-25	Composizione.
ATE470655T1 (de)	2010-06-15	Substituierte 1,5-diaminopentan-3-ol-verbindungen
IS7131A (is)	2004-01-29	Nýjar 2,4-díamínóþíasól afleiður
BR8101523Y1 (pt)	2009-08-11	disposição construtiva aplicada à cadeira.
SE0301847D0 (sv)	2003-06-25	Novel 3,3-Diphenylpropylamines
ES1048499Y (es)	2001-12-16	Persiana compacta.